ISN-001 is under clinical development by Anterogen and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II drugs for Epidermolysis Bullosa have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISN-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISN-001 overview
ISN-001 (ALLO-ASC) is under development for the treatment of perianal fistula, Crohn’s disease, burn wounds, diabetic foot ulcer, epidermolysis bullosa, severe pneumonia caused by the novel coronavirus infection, lateral epicondylitis, burn injury, tendon injury, and fecal incontinence. It is administered as intravenous infusion.
The drug candidate was also under development for the treatment of osteoarthrirtis.
Anterogen overview
Anterogen is a pharmaceutical company. The company compasses in research, development and marketing of cell therapy products. It offers Cupistem injection, an adipose-derived stem cell therapy product for the treatment of Crohn’s fistula; Queencell for the regeneration of subcutaneous adipose tissue; Adipocell for the treatment of depressed scars; and Remodulin injection for the treatment of pulmonary arterial hypertension. The company also provides services such as stem cell banking and analysis service. Anterogen operates in South Korea, where it is headquartered in Geumcheon-gu, Seoul, Republic of Korea (South Korea).
For a complete picture of ISN-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
